$TVTX daily chart
Travere is down about 4.9% at
$50.22 and the day's low so far is
$49.50, right on the zone a lot of us have been watching. The latest items: a Form 144 filed Oct 15 for the CEO (a notice of intent to sell 243,735 restricted shares, which is a routine filing but worth knowing about) and, on Oct 2, the announcement of nine data presentations for ASN Kidney Week, including the final two-year SPARTAN data on FILSPARI in IgAN.
Now the chart, and this is my own read as the author. The
$49.5-50 area is the level I am keeping on my screen: the stock bounced from
$48.98 on Jun 12, and it is where this selloff from
$64.7 in mid-September has arrived. To me it looks like a very strong daily support zone and a candidate floor from which a rebound could start. It is an observation, not a recommendation: support levels fail, and a daily close clearly below it would change the picture. Above, the 20-day SMA is near
$56.4 and the 50-day near
$61.4, and RSI(14) is about 27. The 200-day sits near
$45.9.
Analysts (Finviz): consensus target
$75.21. Named: Guggenheim Buy, PT
$89 from
$75 (Sep 24); Piper Sandler upgraded to Overweight,
$49 (Apr 14).
Next catalyst: ASN Kidney Week, Oct 21-25, Denver, with oral presentations on Oct 23-24.
The full Travere hub (FILSPARI, IgAN, FSGS) is on the Merlintrader site.
Chart: Finviz (affiliate) https://www.merlintrader.com/go/fv/TVTX
Not investment advice.
